OvaGene Oncology Joins The Gynecologic Oncology Group (GOG) Industry Collaboration Team to Advance Gynecologic Cance... (inically useful tests to market for impr...)

HOME >> MEDICINE >> TECHNOLOGY

OvaGene Oncology Joins The Gynecologic Oncology Group (GOG) Industry Collaboration Team to Advance Gynecologic Cancer Research

Date:8/4/2010

inically useful tests to market for improved patient care and outcome."

Dr. Neil Finkler, M.D., Chief Medical Officer for OvaGene stated, "We are very enthusiastic about this collaboration. The ability to run our clinical studies on archived tissues from the GOG, as well as future prospective trials, adds an additional level of validation and scientific review to our studies that will ultimately improve the quality of our product offerings leading to improved patient care."

About OvaGene Oncology

OvaGene Oncology is a molecular diagnostics company, located in Orange County California, dedicated to improving cancer care and outcomes for gynecologic cancer patients through the development of novel gene-based assays. The company plans to offer proprietary and non-proprietary molecular diagnostic assays to assist physicians in the prognosis of gynecologic cancers as well as therapy selection, including radiation and chemotherapy. There are over 11,000 cases of cervical cancer, 25,000 cases of ovarian cancer and 42,000 cases of endometrial cancer diagnosed each year in the United States. The total market for OvaGene's genomic assays is over 80,000 gynecologic cancer cases diagnosed annually. Please visit our website at www.ovagene.com for more information about our company.

About The Gynecologic Oncology Group

The Gynecologic Oncology Group ("GOG") is a national organization dedicated to clinical research in the field of gynecologic cancer. It is one of the coo
'/>"/>

SOURCE OvaGene Oncology Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine technology :

1. OvaGene Oncology Opens New Innovative Gynecologic Cancer Laboratory and Research Facility
2. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
3. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
6. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
7. University of Pennsylvania School of Medicine Study Shows Significant Differences in English- and Spanish-speakers Use of Oncology Websites
8. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
9. Pharsight Uses FDA Disease Model to Support Oncology Drug Development
10. US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer Symposium
11. IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology

Post Your Comments:

(Date:6/19/2013)... 19, 2013 NextDocs announced today that ... research organization, at DIA 2013 , the Drug ... present case studies that explore best practices for making ... trial master file (eTMF) systems. Sharon ... alongside Krystyna Kowalczyk , executive vice president of ...

(Date:6/19/2013)... June 19, 2013 Finesse Solutions, Inc, a ... sciences process applications, announced the launch of its ... cell culture and fermentation. The 3L glass vessels ... of Finesse bioreactors and are designed to optimize ... are fully compatible with all Finesse G3Lab controllers, ...

(Date:6/19/2013)... , June 19, 2013 ... recently added DrugPatentWatch to its extensive ... ) (Logo: http://photos.prnewswire.com/prnh/20130128/590935) ... information on pharmaceutical, drug patents and ... the critical business functions of patent ...

Breaking Medicine Technology:NextDocs and Novella to Present on eTMF at DIA 2013 2 Finesse Solutions Launches Next Generation SmartGlass 3L Bioreactors for Cell Culture and Fermentation 2 Drug Patent Watch 2 Drug Patent Watch 3

[0] NextDocs and Novella to Present on eTMF at DIA 2013 [0] Finesse Solutions Launches Next Generation SmartGlass 3L Bioreactors for Cell Culture and Fermentation [0] Drug Patent Watch

... to be held on Wednesday, August 6, 2008 at 8:00 ... ... 5 Isolagen(TM), Inc. (Amex:,ILE) announced today positive top-line efficacy and safety ... the,Isolagen Therapy(TM) for the treatment of nasolabial folds, or wrinkles.,Each study, conducted ...

... WHIPPANY, N.J., Aug. 5 Nexgen Spine, a ... treatment of,degenerative disc disease, announced today that it ... Lumbar Artificial Disc in the European,Union., "We ... has,received CE mark approval," said Alastair Clemow, Ph.D., ...

Cached Medicine Technology:Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant 2 Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant 3 Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant 4 Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant 5 Nexgen Spine Receives CE Mark Approval for the Physio-L(R) Artificial Disc 2

Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant Nexgen Spine Receives CE Mark Approval for the Physio-L(R) Artificial Disc

(Date:6/20/2013)... June 20, 2013 Footwear etc. is pleased ... USA , and has received many new styles and colors ... models, and models never before introduced in the U.S. The ... loyal following of MBT customers. , MBT shoes feature a ... on sand. This sole also provides outstanding shock absorption, and ...

(Date:6/20/2013)... June 20, 2013 TASC, a ... announced a new service to deal with funding ... the Patient Protection & Affordable Care Act (PPACA), ... health outcomes, clinical effectiveness, and appropriateness" of different ... and conduct its own, with funding in part ...

(Date:6/20/2013)... David Icke, the highly visible alternative researcher and ... , Fresh from the Bilderburg fringe festival and the ... to launch ‘The Peoples Voice’ TV and Radio station by ... opportunity for journalists to cover the stories and investigations that ... globe. , Because this station is for the people, ...

(Date:6/20/2013)... Sydney, Australia (PRWEB) June 20, 2013 ... , research was presented recently, that can show similarities ... food. This could explain the current global obesity ... be addicted to food just as one can be ... Neuroscience and Applied Cognitive Science at the University of ...

(Date:6/20/2013)... 2013 HIPAA One aims ... through a HIPAA Security Risk Analysis using the simplest ... extends the reach of all the HIPAA programs by ... Privacy Officers, security professionals, and members of the Healthcare ... policies and procedures. The new Web site features ...

Breaking Medicine News(10 mins):Health News:Footwear etc. Announces New MBT Shoes for Spring/Summer 2 Health News:TASC Service Helps Employers Handle New Burdens for Health Reimbursement Arrangement Plans 2 Health News:Research Suggests That Unhealthy Food Addiction Could Explain Global Obesity Epidemic 2 Health News:Modern Compliance Solutions Launches a New Web Site Promoting the Industry-Proven, Web-Based HIPAA One Security Solution 2

[0] Footwear etc. Announces New MBT Shoes for Spring/Summer [0] TASC Service Helps Employers Handle New Burdens for Health Reimbursement Arrangement Plans [0] David Icke to Launch Global TV and Radio Station Called The People's Voice [0] Research Suggests That Unhealthy Food Addiction Could Explain Global Obesity Epidemic [0] Modern Compliance Solutions Launches a New Web Site Promoting the Industry-Proven, Web-Based HIPAA One Security Solution

... - Sanofi Pasteur committed to increasing its seasonal ... production capacity in the U.S. -SWIFTWATER, Pa. and ... vaccines division of sanofi-aventis Group (EURONEXT: SAN and ... the U.S. Food and Drug Administration (FDA) has ...

... May 6 Funds in the FY 2010 budget aimed ... to improve access to outpatient physical therapy services for Medicare ... Therapy Association (APTA). S.Con.Res.13 ... 2009-FY 2014, was passed April 29 by the House of ...

... Mary Bono Mack (CA-45) and Nita Lowey (NY-18) ... and well-being of American youth by reintroducing the ... The bipartisan legislation, broadly supported by such organizations ... cross-sector collaboration for improving the health of young ...

... Team Finance LLC (the "Company"), today announced results for the ... uncollectibles ("revenue less provision") in the first quarter of 2009 ... first quarter of 2008. Same contract revenue less provision ... million in the same period a year ago. In ...

... bare-metal version, studies show , , WEDNESDAY, May 6 ... stents are less likely to become blocked again than ... and heart attacks is virtually identical between the two ... show. , The Swedish results eliminate concerns raised by ...

... of those hospitalized in U.S. is 15, CDC says , , ... of U.S. cases of swine flu continue to be mild, ... be atypically young, federal health officials said Wednesday. , The ... which is younger than occurs with regular seasonal flu, Dr. ...

U.S. FDA Licenses Sanofi Pasteur's New Influenza Vaccine Manufacturing Facility Funds in 2010 Budget Could Increase Access to Care for Medicare Beneficiaries Bono Mack, Lowey Introduce Bill To Improve the Health of Youth Team Finance LLC Announces First Quarter 2009 Results Drug-Coated Stents Better at Keeping Arteries Open Younger Age of More Severe Swine Flu Cases Worries Experts

The Atria 6100 delivers the highest level of clinical performance while incorporating cutting-edge technology to streamline clinic workflow. It offers timely, high-quality, and accurate ECG results c...

... The new Guidant VASOVIEW® HemoPro™ ... deliver a new level of ... for both the saphenous vein ... cut-and-seal capability, it lets you ...

Patient Monitor...

...

Medicine Products:

Atria 6100 VASOVIEW® HemoPro™ Endoscopic Vessel Harvesting System PM-9000 Express Patient Monitor BC-3200 Auto Hematology Analyzer